Novavax Inc.
11/13/2024 | Press release | Distributed by Public on 11/13/2024 07:04
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md., Nov. 13, 2024/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.
|
Conference Details: |
|
|
|
Fireside Chat |
|
|
|
Date: |
Wednesday, November 20, 2024 |
|
|
Time: |
11:00 - 11:25 a.m. Greenwich Mean Time |
|
|
Location: |
London, United Kingdom |
|
|
Moderator: |
Roger Song, MD, CFA, Equity Analyst |
|
|
Novavax participants: |
John C. Jacobs, President and Chief Executive Officer and Additional Management Team Members |
|
|
|
|
|
|
Investor Meetings |
|
|
|
Date: |
Wednesday, November 20, 2024 |
Recordings
A replay of the fireside chat will be available on the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxfordand Serum Institute of India'sR21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
[email protected]
Media
Giovanna Chandler
202-709-5563
[email protected]
SOURCE Novavax, Inc.